
Contents	Page No.
Declaration	i
Certificate	ii
Abstract	iii-iv
Acknowledgement	v-vii
List of Abbreviations	viii-xiii
List of Figures	xiv-xx
List of Tables	xxi-xxii
Chapter 1: Introduction and Literature Review	1-33
1 Introduction	1-2
1.1 Types of colon polyps	3-4
1.2 Adenocarcinoma and metastasis	5
1.3 Symptoms of colon cancer	5
1.4 Stages and TNM scores for CRC	6-7
1.4.1 T scores for colon cancer include	7
1.4.2 N scores for colon cancer include	7
1.4.3 M scores for colon cancer include	7
1.5 Types of screening tests	7-8
1.5.1 Two types of FOBT	8
1.6 Treatment for colorectal cancer	8-11
1.6.1 Treating stage 0 colon cancer	9
1.6.2 Treating stage I colon cancer	9
1.6.3 Treating stage II CRC	9
1.6.4 Treating stage III CRC	9-10
1.6.5 Treating stage IV CRC	10-11

1.7 1,3,4-thiadiazoles and its fused ring	11-12
1.7.1 Literature review	12-20
1.8 Research envisaged	21-22
1.9 Hypothesis	22-23
1.10 Objectives of the work	23
1.11 Plan of work	24-25
1.12 References	26-33
Chapter 2: Design, Synthesis and <i>In Vitro</i> Anticancer Screening	34-81
2 Introduction	34-35
2.1 Material and methods	35-43
2.1.1 Docking study	35-36
2.1.2 Prediction of physiochemical properties	36
2.1.3 Molecular dynamic (MD) simulation	36-37
2.1.4 Synthetic Procedure for titled compounds (VR1-VR35)	37
2.1.4.1 Chemistry	37-40
2.1.4.2 Preparation of 2-amino-5-(substituted)-1,3,4-thiadiazole (3a-e)	41
2.1.4.3 Synthesis of 4-substituted benzaldehyde (6a-d)	41
2.1.4.4 Synthesis of substituted 1,3,4-thiadiazole derivatives (VR1-35)	41
2.1.4.5 Characterizations	41-42
2.1.4.6 Anticancer activity	42
2.1.4.7 <i>In vitro</i> IL2, IL6 and COX2 inhibition assays	42-43
2.2 Results	44-77
2.2.1 Design	43
2.2.2 Docking study	43-51
2.2.3 Prediction of ADME properties	51-54
2.2.4 Molecular dynamic (MD) simulation	55-56
2.2.5 Chemistry	57-58

2.2.6 Characterization of synthesized compounds	58-72
2.2.7 Human cancer cell line based study	72-76
2.2.8 Structure-activity relationship (SAR)	76
2.2.9 <i>In vitro</i> IL2, IL6 and COX2 inhibition assays	76-77
2.3 Discussion	77-79
2.4 References	80-81
Chapter 3: Pharmacophore and 3D-QSAR Modeling	82-102
3. Introduction	82
3.1 Material and methods	82-92
3.1.1 Design and database	82-85
3.1.2 Generation of pharmacophore models	85-87
3.1.3. Finding and scoring of common pharmacophore	87-90
3.1.4. Building of 3D-QSAR models	90-92
3.2. Results	92-98
3.2.1. Pharmacophore generation and 3D-QSAR building	92-97
3.2.2. QSAR visualization	98
3.3 Discussion	99-100
3.4 References	101-102
Chapter 4: Acute Toxicity and Pharmacokinetic Studies	103-121
4. Introduction	103
4.1 Materials and Methods	103-107
4.1.1 Chemicals and reagents	103
4.1.2 Procurement and acclimatization of animals	103-104
4.1.2.1 Acute toxicity protocol	104
4.1.2.2 Pharmacokinetics studies protocol	104
4.1.3 Measurements of body weight	104
4.1.4 Estimation of oxidative stress parameters	105-107
4.1.4.1 Tissue malonaldehyde (MDA)	105
4.1.4.2 Tissue protein carbonyl (PC)	105

4.1.4.3 Tissue glutathione (GSH)	106
4.1.4.4 Tissue superoxide dismutase (SOD)	106
4.1.4.5 Tissue catalase (CAT)	107
4.1.5 Biochemical estimations	108
4.1.5.1 Plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT)	108
4.1.5.2 Lactic dehydrogenase (LDH) and alkaline phosphatase (ALP)	108
4.2. Pharmacokinetic study	107-109
4.2.1 Preparation of working reference and standard solutions	107-108
4.2.2 Sample extraction optimization, preparation of calibrants and test samples	108-109
4.2.3 HPLC optimization	109
4.2.4 Stability Studies	109
4.2.5 Method development and validation	109
4.3 Results	110-117
4.3.1 Acute toxicity studies	110-113
4.3.1.1 Evaluation of physiological and biochemical parameters in liver and various enzyme levels in serum	110-112
4.3.1.2 Histopathological assessments of liver	113
4.3.2 Pharmacokinetic study	114-117
4.3.2.1 Optimization of plasma sample pre-treatment conditions	114
4.3.2.2 Method validation	115-116
4.3.2.3. Pharmacokinetic profiles	116-117
4.4 Discussion	118-119
4.5 References	120-121
Chapter 5: <i>In Vivo</i> anti-Colorectal Cancer Activity and ¹H-NMR Based Studies	121-164

5. Introduction	121-122
5.1 Materials and methods	123-124
5.1.1 Drugs and reagents	124
5.1.2 Animals	124
5.1.3 Acute oral toxicity study	124
5.1.4 Experimental protocol	124-125
5.1.4.1 Measurement of physiological parameters in colonic sites	125
5.1.4.2 Determination of enzyme levels in serum	125
5.1.4.3 Determination of oxidative stress parameters	125-126
5.1.4.4 Histopathology and scanning electron microscopy (SEM) analyses	126
5.1.4.5 ELISA (Enzyme-Linked Immunosorbent Assay) experiment	126
5.1.4.6 Quantitative real-time polymerase chain reaction (qRT- PCR) analysis	126-127
5.1.4.7 Western blot analysis	127-128
5.1.4.8 ¹ H-NMR based metabolomics spectroscopy	128
5.1.4.8.1 Sample preparation	128
5.1.4.8.2 ¹ H -NMR processing	128-129
5.1.4.8.3 Spectral assignment	129
5.1.4.8.4 Multivariate Statistical Analysis	129-131
5.1.4.8.5 Pathway Analysis	131-132
5.2 Results	132-153
5.2.1 Evaluation of physiological and biochemical parameters in colon and various enzyme levels in serum	132-134
5.2.2 Determination of oxidative stress parameters	135-136
5.2.3 Histopathology and SEM analysis of colon tissue	136-137
5.2.4 Effects of VR24 and V27 on IL2, IL6, COX2 levels in the colonic tissue	137-138

5.2.5 mRNA expression of the effector's cytokine IL6 and COX2 during DMH-induced CRC	138-139
5.2.6 Western blot analysis	140
5.2.7 ¹ H-NMR-based metabolomics to access the biochemical impact of VR24 and VR27	140
5.2.7.1 Spectral assignment	140-141
5.2.7.2 Serum Metabolic profiling using 1D ¹ H-NMR	142-150
5.2.7.3 Pathways analysis	150-153
5.3 Discussion	154-158
5.4 References	159-164
Chapter 6: Summary and Conclusion	165-171
Appendix-I	172-175
Appendix-II	176
Appendix-III	177
Appendix-IV	178